ReviewInternational journal of nanomedicine2025
Intranasal and Pulmonary Lipid Nanoparticles for Gene Delivery: Turning Challenges into Opportunities.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An inhalable dry powder co-delivery system of ciprofloxacin liposomes and S-nitrosoglutathione for synergistic treatment of Pseudomonas aeruginosa biofilm-associated pulmonary infections.Drug delivery and translational research · 2026Article
- An LNP antiviral siRNA drug cocktail delivered intranasally is effective against a range of respiratory viruses.Virology journal · 2026Article
- Physiological Barriers to Nucleic Acid Therapeutics and Engineering Strategies for Lipid Nanoparticle Design, Optimization, and Clinical Translation.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delivery of nano-therapeutics through the nasal route offers a promising approach for several applications, including intranasal conditions, pulmonary delivery, brain targeting, and vaccination. Despite its potential, this method faces significant challenges, including overcoming the mucosal barrier, ensuring consistent absorption, controlling the deposition area, and managing immunogenic responses. This review provides a comprehensive overview of the current state of nasally delivered lipid nanoparticles (LNPs) for gene medicine, focusing on the specific barriers encountered in this delivery route and strategies to overcome them. We examine how formulation composition affects stability during aerosolization, analyze the impact of particle characteristics on mucociliary clearance, and evaluate interactions with the lung surfactant layer. The review also compares delivery devices including metered-dose inhalers, dry powder inhalers, and nebulizers, highlighting how device selection influences LNP integrity and deposition patterns. Furthermore, we explore potential safety considerations with intranasal LNPs and propose approaches to mitigate adverse effects. By addressing these challenges with evidence-based strategies, this review aims to advance the development and clinical application of intranasal and pulmonary LNP delivery systems for gene-based therapeutics and vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.